Clinical Trials Logo

Clinical Trial Summary

Allergy is defined as a specific abnormal and excessive reaction of the immune system to exposed allergen . This reaction is reproducible with each new exposure allergen . A recent study by The European Academy of Allergy and Clinical Immunology" (EAACI) estimates that 30% of the population suffers from allergic rhinitis and/or conjunctivitis, 20% of children suffer from asthma, and 8% of the population suffers from food allergies in Europe, with a clear increase in prevalence. Allergenic immunotherapy (AIT) remains a corner stone in the treatment of allergic diseases. It involves administering an increasing dose of allergens to induce immunological tolerance. The efficacy and safety of ITA have already been demonstrated. However, patient response is highly heterogeneous. This findinf illustrates the value of biomarkers in the selection of patients, enabling prediction of response to ITA and follow-up.


Clinical Trial Description

This is a prospective, observationel study conducted in Pneumology Department at the Military Hospital in collaboration with the Immunology Laboratory We followed patients in 2 groups: Group 1: patients with asthma or allergic rhinitis who had received allergen immunotherapy (AIT). Group 2: patients with asthma or allergic rhinitis who received a conventional treatment ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06021912
Study type Observational
Source General Administration of Military Health, Tunisia
Contact SELSABIL DABOUSSI, MD
Phone 21629424692
Email selsabilhmpit@gmail.com
Status Recruiting
Phase
Start date March 1, 2023
Completion date March 30, 2024